The news: The FDA asked GLP-1 drugmakers Novo Nordisk and Eli Lilly to remove suicide risk warnings from their weight loss medications
Most patients experience mild symptoms, but proactive management prevents escalation in month 2
95% CI, 0.77-1.63), a sulfonylurea (HR = 1.32
This could explain why tirzepatide (which stimulates the GIP pathway in addition to GLP -1) can be administered at higher doses than semaglutide (which only stimulates GLP-1), without amplifying the side effects typical of GLP-1 agonists (nausea, vomiting)
Final Verdict: Is GLPro GLPatch Worth Trying in 2026
Studies suggest that people who lose weight quickly, particularly with the aid of medications like GLP-1 receptor agonists, may have a higher likelihood of developing gallstones, which can cause severe abdominal pain and may require surgical intervention